People: Akari Therapeutics PLC (AKTX.OQ)
Dr. David Horn Solomon has been appointed as Chief Executive Officer of the Comapny, with effective from August 28, 2017. Dr David Horn Solomon was the CEO of Zealand Pharma A/S (NASDAQ:ZEAL) from 2008 to 2015. Under David's leadership the company went public on NASDAQ OMX in Copenhagen and its lead product, Adlixin®, a GLP-1 receptor agonist for the treatment of type II diabetes, was approved in the US and globally and is now marketed by Sanofi as a monotherapy and in combination with Lantus as Soliqua®. David was also the CEO of Bionor Pharma ASA (OSL:BIONOR) and until his appointment at Akari was the Managing Partner of Sund Capital, a Nordic healthcare investment fund. Dr Solomon studied at Weil Cornell Medicine of Cornell University and its Graduate School of Medical Science where he received his Ph.D.
|Total Annual Compensation,||--|
|Restricted Stock Award,||--|
|Long-Term Incentive Plans,||--|
|Fiscal Year Total,||--|